Monoglycosylated chimeric HA (cHA_mg) with consensus H5 head and consensus H1 stem antigens or C34-adjuvanted monoglycosylated HA stem (HA stem_mg); aimed at eliciting high titers of cross-reactive antibodies against a range of influenza strains and subtypes through CD4+ and CD8+ T cell responses.

Dual-site specific conjugation of M2e peptide with the CRM₁₉₇ carrier protein under denaturation.

Recombinant protein, NMHC, consisting of viral conserved epitopes and a superantigen fragment

A novel rM2e-ΔPly protein containing multiple M2e originated from different species of IAV expressed in Escherichia coli (E. coli)

Chimeric M2e and H3 hemagglutinin (HA) stalk protein vaccine engineered by genetically linking M2e repeat to the engineered H3 stalk domain with stabilizing HA1 N- and C-terminal region and point mutations

Computationally engineered consensus NA sequences forming 3 recombinant NA proteins.

Recombinant protein based vaccine containing the NP antigen adjuvanted with a TLR2/6 agonist, the BPPcysMPEG adjuvant

Novel constructs of recombinant mosaic and chimeric HA, expressed as soluble trimeric proteins; aimed at inducing broadly protective immune responses to influenza A and B strains.

Recombinant influenza virus N1 neuraminidase vaccine candidate, N1-MPP, adjuvanted with CpG 1018, a TLR9 agonist, designed to contribute to the development of a broadly protective NA-based influenza virus vaccine candidate.

Group 1 HA stem-based antigen, based on an approach that removes the immunodominant HA head region while stabilizing the structure of the stem region; aimed at inducing broadly neutralizing antibodies.

Chimeric protein targeting M2e, HA and NP viral proteins; aimed at inducing influenza virus-specific antibody responses, cytotoxic T lymphocyte activity, and antibody-dependent cellular cytotoxicity.

Linear peptide constructs based on the N-terminal sequence of M2e (nM2e) and a helper T-cell epitope.

Multi-epitope unconjugated and CRM-conjugated peptides targeting HA, NA and M2e; formulated with ALFQ (Army liposomal) adjuvant

Synthetic long peptides (SLP) from immunogenic MHC class I-binding CD8+ T cell epitopes covalently attached to an α-galactosylceramide adjuvant, a natural killer T cell agonist; aimed at stimulating influenza-specific memory cytotoxic T lymphocytes and cross-protective immune responses against conserved IAV epitopes.

Novel approaches for constructing HA stem-fragment immunogens; aimed at overcoming HA head immunodominance and stimulating anti-stem germinal center B cell and antibody responses.

Targeting strategy that shuttles M2e to a specific dendritic cell subset (cDC1) by engineering a recombinant anti-Clec9A monoclonal antibody fused at each of its heavy chains with three copies of M2e

Recombinant chimeric protein 3M2e-HA2-NP containing conserved regions of M2e, HA, and NP derived from influenza A virus.

Recombinant protein construct, based on the conserved protein NP and protein transduction domain TAT; aimed at inducing cross-protective cellular and humoral immune responses.

Recombinant protein based construct targeting the HA stalk domain (HAsd) displayed on the surface of L. lactis; aimed at providing cross-immunity against divergent influenza A viruses.

Antigen consisting of 3 tandem M2e repeats plus HA2, in combination with a detoxified anthrax edema toxin (EFn plus PA); aimed at eliciting antigen-specific IgG responses; administered intranasally.

A recombinant full-length soluble trimeric HA protein expressed in mammalian Expi293F expression system administered intradermally and with Addavax adjuvant

Adjuvanted recombinant nucleoprotein construct; aimed at generating cellular and humoral immunity to conserved influenza A proteins.

M2e peptide chemically cross-linked to a mAb specific for DEC-205, a C-type lectin present on dendritic cells, to induce heterosubtypic protection.

COBRA (computationally optimized broadly reactive antigens) generated N1-I NA vaccine designed to cross react with avian, swine and human influenza viruses of N1 NA subtype.

Chimeric HAs (cHAs) generated with consensus sequence building aimed at inducing cross-reactive antibodies.

H5-based HA mini-stem protein folding as a trimer in a pre-fusion confirmation of the HA stem; uses a quarter of full length HA to focus the immune response to the conserved epitope of known broadly neutralizing antibodies in the stem domain of HA.

Novel constructs based on ADCC-inducing peptide in the HA1 and HA2 regions.

Monomeric IgG Fc fused to influenza virus hemagglutinin (HA) Ag with a trimerization domain

Chemically coupled peptide derived from head domain of PR8 HA with HA stem protein.

COBRA HA vaccine coadministered intranasally with a novel adjuvant. Adjuvants include PEI-Ox-DEX hydrogel, M7-CpG, and cGAMP MPs

Molecular clamp which utilizes the highly stable trimerization domain to allow for efficient production and purification of conformationally stabilized perfusion hemagglutinin HA

Novel chimeric HA protein (cH7/3) comprised of the stem domain from seasonal H3 HA and the head domain from avian H7.

M2e antigen based vaccine formulated with Advax-SM adjuvant administered to mothers aimed at inducing passive maternal protection to newborns

An HA stem vaccine grafted with an epitope of broadly neutralizing antibodies CR8071 to stabilize the stem HA domain

Deglycosylated modified HA proteins from H3N2 with various lengths of glycans administered intramuscularly